DZD9008

Phase 2Small molecule

DDizal Pharmaceuticals

DZD9008 is one of 53 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerCompleted

Locally Advanced or Metastatic NSCLCRecruiting

Non-Small Cell Lung CancerPhase 1

Completed

Locally Advanced or Metastatic NSCLCPhase 2

Recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Carboplatin Plus Paclitaxel

Bayer

Phase 3

2 2

HB1801

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 3

2 3

HLX17

Shanghai Henlius Biotech

Phase 3

2 4

DZD9008

DDizal Pharmaceuticals

Phase 2

2 5

Remeron

OOrganon and Co

Preclinical

1 6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

PD-1 Inhibitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT05559645

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Completed·DDizal Pharmaceuticals·Phase 1·NCT05926180·25 enrolled

DZD9008 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With EGFR Mutations: Cohort Study

Recruiting·PPeking Union Medical College Hospital·Preclinical·NCT05559645·180 enrolled

Adult1 trial

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

Completed·DDizal Pharmaceuticals·Phase 1·NCT04909242·78 enrolled

Drug Interactions1 trial

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Completed·DDizal Pharmaceuticals·Phase 1·NCT05418582·40 enrolled

Locally Advanced or Metastatic NSCLC1 trial

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Recruiting·DDizal Pharmaceuticals·Phase 2·NCT06276283·60 enrolled

Hepatic Impairment1 trial

DZD9008 PK Study in Hepatic Impairment Subjects

Completed·DDizal Pharmaceuticals·Phase 1·NCT06084104·17 enrolled

1 more indication

Lymphoma1 trial

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Withdrawn·DDizal Pharmaceuticals·Phase 1/2·NCT04148742

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for DZD9008. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DZD9008 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DZD9008. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Dizal Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: DDizal Pharmaceuticals

DZD9008

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer2 trials

Adult1 trial

Drug Interactions1 trial

Locally Advanced or Metastatic NSCLC1 trial

Hepatic Impairment1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News